Zobrazeno 1 - 10
of 137
pro vyhledávání: '"K. R. Desikan"'
Autor:
K. R. Desikan, David H. Vesole, Elias Anaissie, Sundar Jagannath, Amir A. Toor, D. Spoon, D. Siegel, Bart Barlogie, Ashraf Badros, A. Fassas, Christopher Morris, Maurizio Zangari, Nikhil C. Munshi, Guido Tricot
Publikováno v:
British Journal of Haematology. 112:242-247
Haematopoietic growth factors, especially granulocyte colony-stimulating factor (G-CSF), are frequently utilized alone for peripheral blood stem cell (PBSC) procurement to avoid the morbidity associated with high-dose chemotherapy (HDT). Moreover, th
Publikováno v:
Current Treatment Options in Oncology. 1:97-103
Waldenström's macroglobulinemia (WM) is a clinical syndrome with diverse prognoses, and not all patients require therapy at diagnosis. Serum beta2 microglobulin is a major prognostic determinant, and asymptomatic patients with low beta2 microglobuli
Publikováno v:
Seminars in Hematology. 37:15-21
High-dose chemotherapy with autologous stem-cell transplant has markedly increased complete response (CR) and event-free survival (EFS) and overall survival (OS) rates in multiple myeloma. In fact, patients with no adverse prognostic factors achieve
Autor:
Nikhil C. Munshi, David S. Siegel, Bart Barlogie, Thomas A. Golper, Athanasios Fassas, Guido Tricot, K. R. Desikan
Publikováno v:
British Journal of Haematology. 105:938-941
Tumour lysis syndrome (TLS), because of its low proliferative activity, is thought to only rarely complicate the treatment of patients with multiple myeloma. However, as more aggressive therapeutic approaches are increasingly used in the management o
Autor:
Bart Barlogie, K. R. Desikan, Dan Ayers, John Crowley, Sundar Jagannath, David S. Siegel, Jayesh Mehta, D. Spoon, D. Dhodapkar, Guido Tricot, Joshua Epstein, Bruce Cheson, Jeffery R. Sawyer, David H. Vesole, J. Cromer, Elias Anaissie, Seema Singhal, S. Naucke, A. Fassas, S Mattox, Nikhil C. Munshi
Publikováno v:
Blood. 93:55-65
Between August 1990 and August 1995, 231 patients (median age 51, 53% Durie-Salmon stage III, median serum β-2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) with symptomatic multiple myeloma were enrolled in a program that used a series of
Autor:
J R, Sawyer, J L, Lukacs, N, Munshi, K R, Desikan, S, Singhal, J, Mehta, D, Siegel, J, Shaughnessy, B, Barlogie
Publikováno v:
Blood. 92:4269-4278
Multicolor spectral karyotyping (SKY) was performed on bone marrow samples from 50 patients with multiple myeloma (MM) in anticipation of discovering new previously unidentified translocations. All samples showed complex karyotypes with chromosome ab
Autor:
R. H. Rupp, Herbert Kogler, M. V. Patel, H. W. Fehlhaber, R. G. Bhat, Triptikumar Mukhopadhyay, B. N. Ganguli, K. R. Desikan, Suresh Rudra Nadkarni
Publikováno v:
Tetrahedron. 54:13621-13628
A new antifungal macrocyclic lactone maclafungin, belonging to the oligomycin class has been isolated from an actinomycete sp. Y-8521050. The antibiotic, having a molecular formula of C 46 H 80 O 12 , is active against several fungal species. Its str
Autor:
D. Siegel, Guido Tricot, D Bracy, K. R. Desikan, Sundar Jagannath, Nikhil C. Munshi, Clive S. Zent, Carla S. Wilson, Bart Barlogie, Anthony W. Butch
Publikováno v:
Blood. 91:3518-3523
Multiple myeloma (MM) is usually characterized by production of a single serum monoclonal protein of constant isotype and light-chain restriction. Multiple Ig isotypes and isotype switches, which are rare in untreated patients, are reported to be mor
Autor:
D. Siegel, Seema Singhal, S Mattox, Nikhil C. Munshi, Jayesh Mehta, J Nelson, S Tindle, Bart Barlogie, A. Fassas, D Bracy, K. R. Desikan, Guido Tricot, David H. Vesole, Sundar Jagannath
Publikováno v:
Journal of Clinical Oncology. 16:1547-1553
PURPOSE To compare, in the setting of tandem autotransplantations for multiple myeloma (MM), two established methods of peripheral-blood stem-cell (PBSC) procurement with chemotherapy or hematopoietic growth factor alone. PATIENTS AND METHODS Between
Publikováno v:
Leukemia & Lymphoma. 28:501-508
Reinfusion of mobilized peripheral blood stem cells (PBSC) after high dose chemotherapy accelerates hematopoietic recovery. Because of the relatively low content of hematopoietic progenitors in the peripheral blood even after mobilization, multiple l